Format

Send to

Choose Destination
J Am Geriatr Soc. 2017 Sep;65(9):1969-1974. doi: 10.1111/jgs.14956. Epub 2017 Jun 7.

Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia.

Author information

1
Department of Neurology, School of Medicine, Emory University, Atlanta, Georgia.
2
Department of Environmental and Occupational Health, School of Public Health, Emory University, Atlanta, Georgia.
3
Department of Biostatistics and Bioinformatics, School of Public Health, Emory University, Atlanta, Georgia.
4
Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.

Abstract

OBJECTIVES:

To examine the risk associated with the use of proton pump inhibitors (PPIs) of conversion to mild cognitive impairment (MCI), dementia, and specifically Alzheimer's disease (AD).

DESIGN:

Observational, longitudinal study.

SETTING:

Tertiary academic Alzheimer's Disease Centers funded by the National Institute on Aging.

PARTICIPANTS:

Research volunteers aged 50 and older with two to six annual visits; 884 were taking PPIs at every visit, 1,925 took PPIs intermittently, and 7,677 never reported taking PPIs. All had baseline normal cognition or MCI.

MEASUREMENTS:

Multivariable Cox regression analyses evaluated the association between PPI use and annual conversion of baseline normal cognition to MCI or dementia or annual conversion of baseline MCI to dementia, controlling for demographic characteristics, vascular comorbidities, mood, and use of anticholinergics and histamine-2 receptor antagonists.

RESULTS:

Continuous (always vs never) PPI use was associated with lower risk of decline in cognitive function (hazard ratio (HR) = 0.78, 95% confidence interval (CI) =0.66-0.93, P = .005) and lower risk of conversion to MCI or AD (HR = 0.82, 95% CI = 0.69-0.98, P = .03). Intermittent use was also associated with lower risk of decline in cognitive function (HR = 0.84, 95% CI = 0.76-0.93, P = .001) and risk of conversion to MCI or AD (HR = 0.82, 95% CI = 0.74-0.91, P = .001). This lower risk was found for persons with normal cognition or MCI.

CONCLUSION:

Proton pump inhibitors were not associated with greater risk of dementia or of AD, in contrast to recent reports. Study limitations include reliance on self-reported PPI use and lack of dispensing data. Prospective studies are needed to confirm these results to guide empirically based clinical treatment recommendations.

KEYWORDS:

Alzheimer's disease; cognitive functioning; mild cognitive impairment; proton pump inhibitors

PMID:
28590010
PMCID:
PMC5797939
DOI:
10.1111/jgs.14956
[Indexed for MEDLINE]
Free PMC Article

MeSH terms, Substance, Grant support

MeSH terms

Substance

Grant support

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center